Download PDF
Thromb Haemost 2003; 89(05): 803-811
DOI: 10.1055/s-0037-1613465
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion

Marcus E. Carr Jr.
1   Coagulation Special Studies Laboratory, Departments of Medicine and pathology, Virginia, USA
6   Richmond Veterans Administration Medical Center Richmond, Virginia, USA
,
Erika J. Martin
1   Coagulation Special Studies Laboratory, Departments of Medicine and pathology, Virginia, USA
3   Pathology College of Virginia Virginia Commonwealth University, Virginia, USA
4   Medical College of Virginia Virginia Commonwealth University, Virginia, USA
,
Jan G. Kuhn
3   Pathology College of Virginia Virginia Commonwealth University, Virginia, USA
5   Central Virginia Center for Coagulation Disorders of MCV Hospitals and
,
Stephanie V. Seremetis
7   Novo Nordisk BioPharmaceuticals Princeton, New Jersey, USA
› Author AffiliationsFinancial support: This study was supported in part by research funding from Novo Nordisk A/S, Copenhagen, Denmark
Further Information

Publication History

Received 07 October 2002

Accepted after revision 26 February 2003

Publication Date:
09 December 2017 (online)

  PDF Download  Permissions and Reprints

Summary

While recombinant factor VIIa (rFVIIa) shows promise as a broad-spectrum hemostatic agent, questions remain regarding the most appropriate dose and the best way to monitor its effects. In this study we tested the sensitivity of a thrombin dependent platelet assay, platelet contractile force, to the effects of rFVIIa in normal, factor-deficient, and inhibitor-containing blood samples. Dose dependent effects of rFVIIa on platelet contractile force (PCF) and clot elastic modulus (CEM) were measured in all blood samples.

rFVIIa minimally affected PCF and CEM in normal blood clotted with thrombin or batroxobin. While rFVIIa minimally altered PCF and CEM in factor VIII (FVIII) deficient blood clotted with thrombin, rFVIIa increased PCF and CEM and shortened the lag phase in a dose dependent manner in batroxobin-induced clots. The effects of rFVIIa in factor IX (FIX) deficient blood mirrored the effects seen in FVIII deficient samples. Whether clotted with thrombin or batroxobin, baseline PCF and CEM were abnormally low in FVIII deficient samples containing FVIII inhibitors. In such samples, rFVIIa caused dose dependent improvement of PCF, CEM, and lag phases. In one patient with a spontaneous inhibitor, rFVIIa caused dose dependent increases in PCF and CEM in blood clotted with either enzyme.

rFVIIa corrects the deficient thrombin generation seen in FVIII and FIX deficiency, and in blood containing FVIII inhibitors. As a consequence, platelet function is improved and clot structure is enhanced. Platelet contractile force and clot elastic modulus measurements are sensitive to the dose dependent effects of rFVIIa.

Keywords

Recombinant FVIIa - hemophilia - platelet contractile force - clot elastic modulus - thrombin generation
 

  • References

  • 1 Kristensen J, Killander A, Hippe E.. et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26 (Suppl. 01) Suppl 159-64.
    PubMedGoogle Scholar
  • 2 Vlot JA, Ton E, Machaag AJC, Kramer MHH, Gaillard CAJM.. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VIIa. Am J Med 2000; 108: 421-2.
    CrossrefPubMedGoogle Scholar
  • 3 Kenet G, Walden R, Eldad A, Martinowitz U.. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
    CrossrefPubMedGoogle Scholar
  • 4 Monroe DM, Hoffman M, Allen GA, Roberts HR.. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost 2000; 26: 373-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U.. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001; 114: 114-20.
    CrossrefPubMedGoogle Scholar
  • 6 Carr ME, Shen LL, Hermans J.. Mass-Length Ratio of Fibrin Fibers from Gel Permeation and Light Scattering. Biopolymers 1977; 16: 1-15.
    CrossrefPubMedGoogle Scholar
  • 7 Carr Jr ME, Hermans J.. Size and density of fibrin fibers from turbidity. Macromolecules 1978; 11: 46-50.
    CrossrefPubMedGoogle Scholar
  • 8 Blomback B, Carlsson K, Hessel B, Liljeborg A, Procyk R, Aslund N.. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
    CrossrefPubMedGoogle Scholar
  • 9 Bale MD, Ferry JD.. Strain enhancement of elastic modulus in fine fibrin clots. Thromb Res 1988; 52: 565-72.
    CrossrefPubMedGoogle Scholar
  • 10 Carr Jr ME, Zekert SL.. Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma. Am J Physiol 1994; 266: H1195-201.
    PubMedGoogle Scholar
  • 11 Gabriel DA, Muga K, Boothroyd EM.. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267: 24259-63.
    PubMedGoogle Scholar
  • 12 Carr Jr ME, Dent RM, Carr SL.. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med 1996; 128: 83-8.
    CrossrefPubMedGoogle Scholar
  • 13 Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW.. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-61.
    CrossrefPubMedGoogle Scholar
  • 14 Mullin JL, Norfolk SE, Weisel JW, Lord ST.. Clot lysis of variant recombinant fibrinogens confirms that fiber diameter is a major determinant of lysis rate. Ann N Y Acad Sci 2001; 936: 331-4.
    PubMedGoogle Scholar
  • 15 Hemker HC, Giesen PL, Ramjee M, Wagenvoord R, Beguin S.. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589-91.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Carr ME, Carr SL, Greilich PE.. Heparin ablates force development during platelet mediated clot retraction. Thromb Haemost 1996; 75: 674-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Carr ME, Carr SL.. At high heparin concentrations, protamine concentrations which reverse anticoagulant effects are insufficient to reverse heparin antiplatelet effects. Thromb Res 1994; 75: 617-30.
    CrossrefPubMedGoogle Scholar
  • 18 Carr ME, Zekert SL.. Measurement of platelet-mediated force development during plasma clot formation. Am J Med Sci 1991; 302: 13-8.
    CrossrefPubMedGoogle Scholar
  • 19 Carr ME, Hines S, Carr SL, Todd WM, Taylor TL, Mohanty L.. Storage pool disease in chronic lymphocytic leukemia: abnormal aggregation and secretion without bleeding. Am J Med Sci 1997; 313: 176-81.
    PubMedGoogle Scholar
  • 20 de Gaetano G, Bottecchia D, Vermylen J.. Retraction of reptilase-clots in the presence of agents inducing or inhibiting the platelet adhesion-aggregation reaction. Thromb Res 1973; 2: 71-84.
    CrossrefPubMedGoogle Scholar
  • 21 de Gaetano G, Franco R, Donati MB, Bonaccorsi A, Garattini S.. Mechanical recording of reptilase-clot retraction: effect of adeno-sine-5’-diphosphate and prostaglandin E1 . Thromb Res 1974; 4: 189-92.
    CrossrefPubMedGoogle Scholar
  • 22 Sabovic M, Blinc A.. Biochemical and biophysical conditions for blood clot lysis. Pflugers Arch 2000; 440 (Suppl. 05) (Suppl) R134-6.
    CrossrefPubMedGoogle Scholar
  • 23 Roberts HR, Monroe DM, Oliver JA, Chang JY, Hoffman M.. Newer concepts of blood coagulation. Haemophilia 1998; 4: 331-4.
    CrossrefPubMedGoogle Scholar
  • 24 Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U.. High-dose factor rVIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001; 114: 114-20.
    CrossrefPubMedGoogle Scholar
  • 25 Hoffman M, Monroe DM.. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001; 38: 6-9.
    PubMedGoogle Scholar
  • 26 Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG.. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 923-30.
    CrossrefPubMedGoogle Scholar
  • 27 Carr ME, Carr SL.. Fibrin structure and concentration alter clot elastic modulus but do not alter platelet mediated force development. Blood Coagul Fibrinolysis 1995; 6: 79-86.
    CrossrefPubMedGoogle Scholar
  • 28 Greilich PE, Carr ME, Zekert SL, Dent RM.. Quantitative Assessment of Platelet Function and Clot Structure in Patients with Severe Coronary Artery Disease. Am J Med Sci 1994; 307: 15-20.
    CrossrefPubMedGoogle Scholar
  • 29 Krishnaswami A, Carr Jr ME, Jesse RL, Kontos MC, Minisi AJ, Ornato JP, Vetrovec GW, Martin EJ.. Patients with coronary artery disease who present with chest pain have significantly elevated platelet contractile force and clot elastic modulus. Thromb Haemost 2002; 88: 739-44.
    Article in Thieme ConnectPubMedGoogle Scholar